Literature DB >> 25505215

Non-small cell lung cancer, version 1.2015.

David S Ettinger, Douglas E Wood, Wallace Akerley, Lyudmila A Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T Cheney, Lucian R Chirieac, Thomas A D'Amico, Todd L Demmy, Thomas J Dilling, Ramaswamy Govindan, Frederic W Grannis, Leora Horn, Thierry M Jahan, Ritsuko Komaki, Mark G Kris, Lee M Krug, Rudy P Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W Loo, Renato Martins, Gregory A Otterson, Jyoti D Patel, Katherine M Pisters, Karen Reckamp, Gregory J Riely, Eric Rohren, Steven Schild, Theresa A Shapiro, Scott J Swanson, Kurt Tauer, Stephen C Yang, Kristina Gregory, Miranda Hughes.   

Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) focuses on the principles of radiation therapy (RT), which include the following: (1) general principles for early-stage, locally advanced, and advanced/metastatic NSCLC; (2) target volumes, prescription doses, and normal tissue dose constraints for early-stage, locally advanced, and advanced/palliative RT; and (3) RT simulation, planning, and delivery. Treatment recommendations should be made by a multidisciplinary team, including board-certified radiation oncologists who perform lung cancer RT as a prominent part of their practice.
Copyright © 2014 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2014        PMID: 25505215     DOI: 10.6004/jnccn.2014.0176

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  71 in total

1.  Imaging texture analysis for automated prediction of lung cancer recurrence after stereotactic radiotherapy.

Authors:  Sarah A Mattonen; Shyama Tetar; David A Palma; Alexander V Louie; Suresh Senan; Aaron D Ward
Journal:  J Med Imaging (Bellingham)       Date:  2015-11-12

Review 2.  Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.

Authors:  Meghan Campo; Hani Al-Halabi; Melin Khandekar; Alice T Shaw; Lecia V Sequist; Henning Willers
Journal:  Oncologist       Date:  2016-06-27

3.  The long-waited high level evidence in thoracic surgery.

Authors:  Cheng-Che Tu; Po-Kuei Hsu
Journal:  Ann Transl Med       Date:  2016-10

4.  Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy.

Authors:  Rong Li; Jiang Gu; John V Heymach; Xiang Shu; Lina Zhao; Baohui Han; Yuanqing Ye; Jack Roth; Xifeng Wu
Journal:  Carcinogenesis       Date:  2017-04-01       Impact factor: 4.944

Review 5.  Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?

Authors:  Sarah A Mattonen; Aaron D Ward; David A Palma
Journal:  Br J Radiol       Date:  2016-06-20       Impact factor: 3.039

6.  Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells.

Authors:  Ling Fu; Liang Guo; Yi Zheng; Zhenyu Zhu; Mingyue Zhang; Xiaohua Zhao; Hongxue Cui
Journal:  Oncol Lett       Date:  2018-02-02       Impact factor: 2.967

7.  Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.

Authors:  Mark Zaki; Michael Dominello; Gregory Dyson; Shirish Gadgeel; Antoinette Wozniak; Steven Miller; Peter Paximadis
Journal:  Clin Lung Cancer       Date:  2016-07-22       Impact factor: 4.785

8.  Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.

Authors:  Jennifer Shih; Babar Bashir; Karen S Gustafson; Mark Andrake; Roland L Dunbrack; Lori J Goldstein; Yanis Boumber
Journal:  J Natl Compr Canc Netw       Date:  2015-08       Impact factor: 11.908

9.  Extracapsular extension is a powerful prognostic factor in stage IIA-IIIA non-small cell lung cancer patients with completely resection.

Authors:  Weishuai Liu; Yuejuan Shao; Bingqing Guan; Jianlei Hao; Xianjiang Cheng; Kai Ji; Kun Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 10.  Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.

Authors:  Jun Zhang; Dongkyoo Park; Dong M Shin; Xingming Deng
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-11-17       Impact factor: 3.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.